 WARREN, N.J., Nov. 23, 2020 GLOBE NEWSWIRE -- Bellerophon Therapeutics, Inc. Nasdaq: BLPH Bellerophon or the Company, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Monitoring Committee DMC has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulse for the treatment of COVID-19. 